TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS

Objectives: Patients with MM continue to relapse on current therapies, stressing the need for new immunotherapy targets. GPRC5D is an orphan receptor that is expressed on malignant plasma cells in MM. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that binds to GPRC5D and CD3, redirecting...

Full description

Bibliographic Details
Main Authors:	JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari
Format:	Article
Language:	English
Published:	Elsevier 2021-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137921005125

Similar Items

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Cyrille Touzeau, et al.
Published: (2023-08-01)

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1
by: N. W. C. J van de Donk, et al.
Published: (2022-04-01)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)
by: M.C. Minnema, et al.
Published: (2023-05-01)

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB
by: N. W. van de Donk, et al.
Published: (2022-06-01)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
by: M Mateos, et al.
Published: (2022-04-01)

S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1
by: M. C. Minnema, et al.
Published: (2022-06-01)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
by: Nizar J Bahlis, et al.
Published: (2023-08-01)

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1
by: N. van de Donk, et al.
Published: (2023-05-01)

1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
by: Benjamin Doranz, et al.
Published: (2023-11-01)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
by: Leo Rasche, et al.
Published: (2023-08-01)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-02-01)

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-03-01)

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
by: Susan Bal, et al.
Published: (2023-08-01)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
by: Juanjuan Zhao, et al.
Published: (2023-08-01)

A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
by: Urara Tomita, et al.
Published: (2024-03-01)

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
by: Lien Vandenberk, et al.
Published: (2023-11-01)

BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
by: Ying Liu, et al.
Published: (2023-12-01)

circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide
by: Chaohui Gu, et al.
Published: (2018-12-01)

326 Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma
by: Yuting Zhang, et al.
Published: (2023-11-01)

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: I. Dekhtiarenko, et al.
Published: (2022-06-01)

GPRC5C regulates the composition of cilia in the olfactory system
by: Sneha Bhat, et al.
Published: (2023-12-01)

GPRC5B protects osteoarthritis by regulation of autophagy signaling
by: Liang He, et al.
Published: (2023-07-01)

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
by: Georg Jeryczynski, et al.
Published: (2021-11-01)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
by: P Rodriguez-Otero, et al.
Published: (2022-04-01)

Talquetamab: A promising immunotherapy for multiple myeloma
by: Amna Tariq, et al.
Published: (2023-10-01)

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL
by: C. Hasselbalch Riley, et al.
Published: (2022-06-01)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Surbhi Sidana, et al.
Published: (2023-08-01)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: N. van de Donk, et al.
Published: (2023-05-01)

RhoA/C inhibits proliferation by inducing the synthesis of GPRC5A
by: Lukas Richter, et al.
Published: (2020-07-01)

GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
by: Jie Mei, et al.
Published: (2023-08-01)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
by: Jieyun Xia, et al.
Published: (2023-06-01)

Orphan G-Protein Coupled Receptor GPRC5B Is Critical for Lymphatic Development
by: Wenjing Xu, et al.
Published: (2022-05-01)

GPRC5B a putative glutamate-receptor candidate is negative modulator of insulin secretion.
by: Soni, A, et al.
Published: (2013)

GPRC5B a putative glutamate-receptor candidate is negative modulator of insulin secretion.
by: Soni, A, et al.
Published: (2013)

GPRC5A promotes migration and invasion of human osteosarcoma cell line 143B
by: SONG Qi, CHENG An-yuan, YU Ling, XU Li
Published: (2020-10-01)

Cancer cell adaptation to hypoxia involves a HIF‐GPRC5A‐YAP axis
by: Alexander Greenhough, et al.
Published: (2018-11-01)

Deciphering the molecular regulatory of RAB32/GPRC5A axis in chronic obstructive pulmonary disease
by: Yixing Wu, et al.
Published: (2024-03-01)

Enhancement of lung tumorigenesis in a <it>Gprc5a </it>Knockout mouse by chronic extrinsic airway inflammation
by: Barta Peter, et al.
Published: (2012-01-01)